NCT02357147终止2 期
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Morphotek
- 入组人数
- 124
- 主要终点
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
This study was originally designed as a multicenter, double-blind, randomized, parallel-group study, using a placebo control or amatuximab 5 milligrams per kilogram (mg/kg), administered weekly, designed to evaluate the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin in participants with unresectable Malignant Pleural Mesothelioma (MPM) who have not received prior systemic therapy.
Per a business decision made by the Sponsor, participants who were randomized to amatuximab and were still on active treatment at the time of the protocol amendment may have consented to continue to receive weekly treatment with amatuximab until disease progression or intolerable toxicity at the discretion of the principal investigator. Participants randomized to placebo or who were in follow-up at the time of the amendment have been discontinued from the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are at least 18 years of age at the time of informed consent
- •Have confirmed diagnosis of MPM with the following characteristics:
- •Unresectable disease (defined as the participant not being a candidate for curative surgery)
- •Epithelial type
- •Have an archived tissue sample to be submitted either as a formalin fixed paraffin-embedded (FFPE) tumor block, or 5 to 15 unstained slides
- •Have measurable disease at Screening by computed tomography (CT) (or magnetic resonance imaging [MRI]) as defined by at least 1 lesion of greater than or equal to 1.5 cm in the longest diameter for a non-lymph node or greater than or equal to 1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to the modified RECIST criteria
- •Have other significant medical conditions well-controlled and stable in the opinion of the investigator for at least 30 days prior to Day 1
- •Have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 at Screening
- •Have a life expectancy of at least 3 months, as estimated by the investigator
- •Have adequate organ reserve as determined by laboratory test results obtained within 2 weeks prior to Study Day 1 as indicated below:
- •Absolute neutrophil count greater than or equal to 1.5 x 10^9/L
- •Platelet count greater than or equal to 100 x 10^9/L
- •Hemoglobin greater than or equal to 9 g/dL
- •Serum bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (Participants with serum bilirubin abnormalities greater than this specified limit are eligible only if they have known Gilberts disease)
- •Aspartate aminotransferase less than or equal to 3 x ULN
- •Alanine aminotransferase less than or equal to 3 x ULN
- •Alkaline phosphatase less than or equal to 3 x ULN
- •Have a calculated serum creatinine clearance greater than or equal to 45 mL/min using the Cockcroft-Gault equation
- •Participants of childbearing potential must be surgically sterile or consent to use a highly effective method of contraception throughout the study period. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing). If a participant of childbearing potential is neither surgically sterile nor postmenopausal, highly effective contraceptive measures must start either prior to or at Screening and continue throughout the entire study period and for at least 6 months after the last dose of chemotherapy and at least 30 days after the last dose of Test Article (amatuximab or placebo) is administered (whichever is later). A highly effective method of contraception is defined as one that results in a low failure rate (that is, less than 1% per year) when used consistently and correctly. Periodic abstinence, the rhythm method, the withdrawal method, condoms, and diaphragms are not acceptable methods of contraception. Women of childbearing potential must also refrain from egg cell donation for 6 months after the final dose of investigational product
- •Male participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (that is, not of childbearing potential or practicing highly effective contraception throughout the study period and for 6 months after discontinuation of chemotherapy and for 5 weeks after Test Article (amatuximab or placebo) discontinuation (whichever is later). No sperm donation is allowed during the study period and for 90 days after Test Article discontinuation
- •Be willing and able to provide written informed consent
- •Be willing and able to comply with all aspects of the protocol
- •Participants who were enrolled in the study and randomized to the amatuximab treatment arm may, at the discretion of the principle investigator (PI), consent to continue to receive amatuximab therapy until disease progression, intolerable toxicity, or withdraw of consent
排除标准
- •Have any history of the following:
- •Prior systemic therapy or radiotherapy for MPM; local radiotherapy of noncurative intent (ie, for prevention of instrument-tract recurrence and/or symptom control) is permitted
- •Evidence of other active, invasive malignancy requiring treatment within the past 5 years; noninvasive cancer history (such as carcinoma-in-situ [CIS] that has been resected) is allowed
- •Currently have mesothelioma of the sarcomatous type, mixed histologic disease, or have malignant peritoneal mesothelioma
- •Have confirmed presence of central nervous system metastases
- •Active viral hepatitis or active human immunodeficiency virus infection
- •Have evidence of any other serious systemic disease, including active bacterial or fungal infection, or any medical condition that, in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
- •Clinically significant heart disease (eg, congestive heart failure of New York Heart Association Class 3 or 4, angina not well controlled by medication, or myocardial infarction within 6 months)
- •Electrocardiogram (ECG) demonstrating clinically significant arrhythmias (Note: participants with chronic atrial arrhythmia, ie, atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible). A clinically significant ECG abnormality, including a marked prolonged QT/QTc interval (eg, a repeated demonstration of a QTc interval of greater than 500 ms)
- •Have known intolerance to the Test Article (ie, documented hypersensitivity AE to prior monoclonal antibody therapy, or to amatuximab or any of its excipients)
- •Pregnant and/or lactating females are excluded; a negative beta-human chorionic gonadotropin [B-hCG]) is required during Screening, and a separate local assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of Test Article
- •Have any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in a clinical study
- •Are scheduled for debulking surgery during the study
- •Are currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 x the half-life of the investigational drug/device, whichever is longer) preceding informed consent
- •Participants previously randomized to placebo
- •Participants who have not signed the updated informed consent form associated with this amendment 2
- •Participants who have radiographic or clinical disease progression or intolerable toxicity such that ongoing amatuximab treatment through this study is not appropriate
研究组 & 干预措施
Arm 1
Experimental
Combination Phase - Amatuximab + Pemetrexed and Cisplatin
Maintenance Phase - Amatuximab
干预措施: Amatuximab (Drug)
Arm 1
Experimental
Combination Phase - Amatuximab + Pemetrexed and Cisplatin
Maintenance Phase - Amatuximab
干预措施: Pemetrexed (Drug)
Arm 1
Experimental
Combination Phase - Amatuximab + Pemetrexed and Cisplatin
Maintenance Phase - Amatuximab
干预措施: Cisplatin (Drug)
Arm 2
Experimental
Combination Phase - Placebo + Pemetrexed and Cisplatin
Maintenance Phase - Placebo
干预措施: Placebo (Drug)
Arm 2
Experimental
Combination Phase - Placebo + Pemetrexed and Cisplatin
Maintenance Phase - Placebo
干预措施: Pemetrexed (Drug)
Arm 2
Experimental
Combination Phase - Placebo + Pemetrexed and Cisplatin
Maintenance Phase - Placebo
干预措施: Cisplatin (Drug)
结局指标
主要结局
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
时间窗: Baseline up to 3 years
AEs included both non-SAEs and SAEs and the same participant can have both SAEs and as well non-SAEs.
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)MelanomaNCT01009177Actelion80
已完成
2 期
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid CancerThyroid NeoplasmsNCT00537095Genzyme, a Sanofi Company164
招募中
3 期
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGNIC-MPGNNCT05755386Novartis Pharmaceuticals106
已完成
3 期
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelPulmonary Disease, Chronic ObstructiveNCT04133909GlaxoSmithKline806
已完成
2 期
An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy PatientsPrimary Mitochondrial MyopathyNCT04535609Reneo Pharma Ltd213